The Europe pacemaker market is expected to reach US$ 2,408.5 Mn in 2027 from US$ 1,248.7 Mn in 2018 – GlobeNewswire

Posted on by

New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Pacemakers Market to 2027 - Regional Analysis and Forecasts By Product Type By Technology, By End User, and Country" - https://www.reportlinker.com/p05806319/?utm_source=GNW

The electronic medical implant is an emerging field in the medical industry and has led to various developments of the products, in the field of cardiology, neurology, and otology.Many of the market players are developing novel products in order to minimize the burden of cardiovascular diseases, neurological disorders, and hearing disorders.

For instance, in November 2017, Medtronic launched Azure pacemakers with BlueSync technology that increases the life of the pacemakers, thus reducing the number of device replacements.It also enables to secure and automatic wireless data transmission to physicians.

Similarly, in July 2016, BIOTRONIK headquartered in Germany received CE approval for its new Edora pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps). Moreover, the presence of pacemaker manufacturers in the European region is also likely to influence the pacemaker market in the European region. Osypka Medical GmbH, Cardiac Impulse S.R.L., Sorin Biomedica C.R.M., S.R.L. are manufacturers located in Europe.In 2018, Europe pacemaker market held a market share of 22.8% of the global pacemaker market. The implantable pacemakers segment expected to dominate its market share and was valued at US$ 855.5 Mn in 2018 and is anticipated to reach US$ 1,687.2 Mn by 2027. On the other hand, implantable pacemakers segment is also anticipated to witness the fastest growth rate of 8.0% during the forecast period, 2019 to 2027.Similarly, in 2018 single-chambered pacemaker segment by technology was valued at US$ 890.2 Mn in 2018 and is anticipated to reach US$ 1,736.8 Mn by 2027 and is also expected to grow at the fastest growth rate of 7.9% during the forecast period.Furthermore, the hospitals & clinics segment held the largest market share of is also anticipated to witness the fastest growth rate of 8.0% during the forecast period, 2019 to 2027. This segment is also expected to dominate the market in 2027 as it is the primary care center for most of the population.Some of the major primary and secondary sources for endodontic devices included in the report are, European Commission, European Society of Cardiology, World Health Organization, European Patent Office, International Trade Administration (ITA) among others.Read the full report: https://www.reportlinker.com/p05806319/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original post:
The Europe pacemaker market is expected to reach US$ 2,408.5 Mn in 2027 from US$ 1,248.7 Mn in 2018 - GlobeNewswire

Neurological Disorders | Conditions and Treatments | UCSF …

Posted on by

Neurological disorders are diseases of the brain, spine and the nerves that connect them. There are more than 600 diseases of the nervous system, such as brain tumors, epilepsy, Parkinson's disease and stroke as well as less familiar ones such as frontotemporal dementia.

UCSF Medical Center is one of the top hospitals in the nation in neurology and neurosurgery, according to U.S. News & World Report. We treat conditions from the common to rare and draw on our research to provide the most advanced therapies available.

We have one of the largest brain tumor treatment programs in the United States and one of California's largest cerebrovascular surgery programs. Our advanced treatments include Gamma Knife radiosurgery, which delivers a finely focused, high dose of radiation precisely to its target. It is used to treat small to medium size tumors, epilepsy, trigeminal neuralgia and abnormal blood vessel formations deep in the brain.

In Northern California, we have the only comprehensive memory disorders center and the largest center for the treatment of Parkinson's disease. We also have leading experts in the treatment of peripheral nerve disorders such as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), a progressive degeneration of nerve cells controlling muscle movements.

Neurological support groups for patients and their families are open to the public.

The rest is here:
Neurological Disorders | Conditions and Treatments | UCSF ...

Neurology | Boston Children’s Hospital

Posted on by

Welcome to Boston Children's Hospital's Department of Neurology! We care for infants, children and adolescents with all types of neurologic and developmental disorders. From diagnosis through long-term follow up, we provide compassionate, comprehensive support to help every child reach his or her full potential. Science informs our care today and our work toward better care tomorrow.

Were proud to uphold a historical legacy that dates to 1929, when we became the first dedicated child neurology service at a U.S. pediatric hospital. We went on to establish the countrys first pediatric epilepsy unit (in 1944), the first comprehensive pediatric sleep center (in 1978) and the first dedicated pediatric neurocritical care program (in 1996).

Neurology programs and services: Our neurologists care for children with epilepsy, cerebral palsy, birth defects, muscular dystrophies and other neuromuscular disorders, brain injury and concussion, neurodevelopmental disorders including autism, sleep problems, headache, multiple sclerosis and neuroinflammatory disorders, movement disorders, brain and spinal tumors, cerebrovascular disorders, metabolic disorders and more.

Patient and family resources: How to access our services, preparing for your appointment, care in the community, our patients stories and more.

Boston Childrens Hospital Neurology in the news

7 questions parents should ask in seeking neurologic care: A list of questions to ask when comparing different centers and programs.

U.S. News & World Report has ranked Boston Childrens Hospital as having the nations #1 Neurology/Neurosurgery program. Here are a few reasons:

Comprehensive services: Through nearly 40 specialized programs, we treat more nervous system conditions than any pediatric neurology program in the world, including rare and complex disorders. We offer advanced clinical services including a rapid response team, specialized Level 4 epilepsy care, genetics, rehabilitation programs and biofeedback treatment for headache.

Superior medical capabilities: With more than 60 child neurologists, 10 neuropsychologists and psychologists and 30 nurses and nurse practitioners, we offer highly specialized, individualized care. We have received high marks for medical best practices in neurology and neurosurgery and for use of the most advanced technologies, and have been accredited for high nursing standards by the American Nurses Credentialing Center.

Quality orientation: We collaborate with multiple specialists to ensure the best possible care. All childrens outcomes are tracked in a quality control database. We also share data with the Pediatric Neurocritical Care Research Group and the National Healthcare Safety Network to continually improve care.

Supportive, holistic care: Our broad-based team provides family-centered care to meet each childs medical, emotional and educational needs. A family resource center, family support specialists, pediatric psychologists, social workers and a parent advisory committee are available to you and your child. We also house the hospitals Bullying & Cyberbullying Prevention & Advocacy Collaborative (BACPAC).

Science and innovation: At any given time, our child neurologists are engaged in dozens of clinical trials to test new treatments. Our F.M. Kirby Neurobiology Center is the nations top neuroscience hub with more than two dozen laboratories driving tomorrows treatments. Our doctors and scientists work together to bring advances into patient care.

Read more here:
Neurology | Boston Children's Hospital

Division of Pediatric Neurology | University Hospitals …

Posted on by

The Pediatric Neurology Division at University Hospitals Rainbow Babies & Childrens Hospital is one of the most active service, training and research programs in the upper Midwest of the United States, and is devoted to the diagnosis and care of children with neurological problems.

Since 1997, the Neurology Division at UH Rainbow Babies & Childrens Hospital has expanded to include eight pediatric neurology faculties, two advanced practice nurses and two RNs to provide both outpatient and inpatient consultations for children and their families. Our team provides family-centered care for the full range of neurological challenges to the child and his or her family.

Pediatric neurology faculty are certified by the American Boards of Neurology and Pediatrics. Each physician brings to our Division expertise in specific areas of epilepsy, metabolic-genetic disease, sleep medicine, headaches, neuro-oncology, behavioral and cognitive neurology (including ADHD, Tourettes syndrome and Autism), and the care of multiple-handicapped children including those with cerebral palsy.

Multiple programs are embedded into the Rainbow Neurological Center which is part of the Neurological Institute at University Hospitals Cleveland Medical Center. Integrated service, educational and research programs provide care for children with epilepsy, developmental delay, headaches, brain tumors, stroke, movement disorders, cognitive and behavioral disorders, and neurointensive care and fetal neurology needs.

Continued here:
Division of Pediatric Neurology | University Hospitals ...

Neuropathology | Lewis Katz School of Medicine

Posted on by

An understanding of the pathologic basis of neurologic diseases is essential for understanding both the clinical manifestations of the disease, as well as the potential treatment paradigms.

The focus of the neuropathology rotation is diagnostic aspects of neuropathology including surgical neuropathology , autopsy neuropathology, and neuromuscular pathology. In particular, clinical-pathologic correlations will be stressed. The resident will attend and participate in the weekly neurology/radiology/neurosurgery conference( Friday 9-10am).

In this one month elective, the resident will gain familiarity with both common and rare neuropathologic diseases, develop a solid foundation in morphologic diagnosis, and acquire an in depth understanding of the utility of ancillary techniques such as immunohistochemistry, molecular diagnostics, and electron microscopy.

The program is structured to meet this goal through exposure of the resident to an abundance of diversified case material, a commitment to medical teaching, state-of-the-art clinical laboratory facilities, and a graduated program of assigned responsibilities.

At the end of this rotation the resident should be able to identify normal and pathologic gross and microscopic anatomy, identify the findings in major neuropathologic diseases, and generate appropriate differential diagnoses based upon neuropathologic findings.A pretest will be given at the beginning of the rotation and a post test will be taken at the end of the rotation to document the progress made by the resident during the rotation.

Suggested Reading:

Brain cutting at TUH morgue: Tuesdays 9-10 amCases from the previous weeks are discussed and examined at the gross level focusing on both autopsy neuropathology concepts as well as general neuroanatomy.Autopsy confererences at Multiheaded scope: Tuesdays 8-9 amInteresting findings from the autopsy brains are presented to the residentsMonthly neuropathology lecture/ slide conference: The didactic session cover topics such as CNS infectious diseases, neurodegenerative diseases, and trauma; while the unknown case conferences focus on CNS tumor pathology. For the later, residents are given a series of 5-6 cases with clinical history for review prior to the conference, and asked to formulate a working differential diagnosis for each of the cases.

Read the original here:
Neuropathology | Lewis Katz School of Medicine

Neurology – MU Health Care – Columbia, MO

Posted on by

When you need expert care for diseases affecting your brain, spinal cord or nervous system, the neurologists at University of Missouri Health Care provide the most advanced care in central Missouri.

We offer the widest range of options and the most advanced medical capabilities for neurological disorders in the region, including specialized care for kids.

Neurological diseases involve different parts of the nervous system, so our neurologycare team includes specialists in brain and spinal cordillness, muscle and joint conditions and other medical specialties. We create your care team based on your unique needs.

As an academic health center, MU Health Care has experts in every medical specialty. Thats important for you because it means you can get all your care in a single place. Regardless of your condition, we have the expertise and resources to offer you complete care.

Our neurologists are also researchers and educators, so your care team is knowledgeable about the latest therapies. If theres a promising new treatment, youll find it at MU Health Care including treatments only available through clinical trials. Our doctors are on the forefront of the latest discoveries in neurological disease research.

Neurologicaldiseases require complex care from a number of specialists, so we make your care as convenient as possible. Your care team may include doctors, nurses, dietitians, pharmacists, respiratory and rehabilitation therapists, orthotists (clinicians who specialize in limb and spine braces or prostheses) and other clinicians.

We treat many types of neurological diseases, including:

Your neurologist will design a care plan that helps you maintain as much independence and function as possible. We draw from a variety of services to help improve your quality of life and support you and your family, including:

At MU Health Care, youll receive a full spectrum of personalized neurological care and services.

Read the original post:
Neurology - MU Health Care - Columbia, MO

Neurology & Neurologist Services in Southern New Jersey

Posted on by

Advanced Care for the Brain and Nervous System

Neurology is the branch of medicine that deals with the anatomy, functions, and disorders of the brain, nerves and the nervous system. Neurologists evaluate patients to determine the causes of pain, seizures, confusion and other neurological conditions.

Our neurologists are board certified to evaluate and treat general neurological concerns in addition to specialized conditions like Parkinsons disease, myasthenia gravis, epilepsy and migraines.

Virtua has partnered with Penn Medicine to bring the regions foremost leader in neurological treatment and research to South Jersey. The Penn Medicine Virtua Neurosciences Alliance is another way these two great health systems are working together to ensure the highest level of care is available to Virtua patients and all South Jersey residents.

Stroke is the sudden death of brain cells due to lack of oxygen. It's caused by blockage of blood flow or rupture of an artery to the brain. Sudden loss of speech, weakness, and paralysis on one side of the body are dramatic symptoms of stroke.

When symptoms appear but quickly fade away on their own, it's called a transient ischemic attack or mini-stroke, which is often a precursor to a stroke. Strokes can be diffuse (affecting multiple areas of the brain a little) or focused (affecting one part of the brain a lot). Virtua neurologists are experts in determining the causes of stroke, managing side effects and rehabilitation, and minimizing the risks of having another.

Virtua is investing in new technology to provide long-term epilepsy monitoring at all of its inpatient campuses. Virtua neurologists will be able to continuously monitor seizure activity to fine tune treatments and medication to minimize seizures and side effects.

Penn Medicine offers additional, advanced diagnostics and therapeutic interventions. Specialists at the Penn Epilepsy Center provide comprehensive evaluation and treatment for patients with epilepsy, seizure disorders and all seizure-associated symptoms including memory and mood problems. The program is led by experienced Penn neurologists who are recognized leaders in the research, diagnosis, and medical and surgical treatments for epilepsy.

The Penn Epilepsy Center is recognized by the National Association of Epilepsy Centers (NAEC) as a Level 4 epilepsy center. Level 4 epilepsy centers have the professional expertise and facilities to provide the highest-level medical and surgical evaluation and treatment for patients with complex epilepsy.

Read the original here:
Neurology & Neurologist Services in Southern New Jersey

Community Neurology Center | University Hospitals …

Posted on by

Learn more about UH Neurological Institutes General Neurology Center

University Hospitals Neurological Institutes Community Neurology Center provides expert testing, diagnosis and treatment for diseases of the nervous system at convenient locations throughout the community.

As a University Hospitals Center of Excellence, the center brings together leading experts across many different areas of specialty. They work together and use the latest clinical advances and technologies to benefit patients. In fact, many are involved in nationally funded research and are continuously working to discover future innovations.

The Community Neurology Center is the best starting point for new patients with undiagnosed neurological disorders and those seeking second opinions. Depending on the diagnosis, patients may be referred to one of the specialized centers within UH Neurological Institute, or receive treatment through our community neurology programs.

UH Neurological Institute integrates its wide range of capabilities with our community-based hospitals and medical centers to ensure that patients receive the same high level of innovative, personalized care regardless of location.

Our team of physicians and other specialists has over 60 years of combined experience in diagnosing and treating a full range of neurological disorders. They work closely with UH Neurological Institute specialists experienced in:

Continued here:
Community Neurology Center | University Hospitals ...

What Does It Mean to Be a Good Doctor? – Scientific American

Posted on by

A few years ago, I was shadowing a neurologist at a hospital just down the road from my family home in Connecticut. It was a relatively slow day for the doctor, full of chart reviews and sifting through brain images for abnormalities. As she went about her paperwork, the neurologist shared her insights with me, especially when something exciting popped up. Even then, I remember finding it strange that the human body can be a medical educatorsomething to be studied, even marveled at.

I learned what an ischemic stroke looked like on a CT scan. I saw what electronic health records looked like across an assortment of patients and their health statuses, annotated by past and present health care providers. I read what doctors considered to be objective truths about their patients, truths including data points and test results that were worthy of being documented. I read the things that mattered to insurance companies and provided the doctors their paychecks. I saw a complicated system of documentation that put the medical record and physician reimbursement at the heart of patient-centered health care.

And I read snippets of patients subjective realities of their ailments that the chart authors annotated with phrases like patient insists [x] or patient seems convinced of [y] or even patient comes in frequently, seeking attention. It was as if the narrative of a persons own lived experience was not trustworthy enough for science, or at least not relevant enough to be taken seriously within our fee-for-service model of health care. There was no way a patient could be the first author in their own story, a coveted role reserved for the educated, the objectivethe clinicians.

In the medical field, we often talk about the fine balance between personal responsibility and social determinism in influencing health behaviors. But when patients with real concerns and conditions take their health into their own hands, they are judged, and labeled attention-seekers, when science has no answers for them. Maybe its because objective data is comforting to analytic, medical minds. But when no data exist to explain particular illnesses and when time is money, it becomes easier to view the body in front of you as one of a hypochondriacal, noncompliant or attention-seeking person than to truly listen and strengthen the bond of a doctor-patient relationship. Unfortunately, this attitude doesnt make for good medical care because somehow, while looking through even the most mundane of reading materials that daya patient chart riddled in complicated medical jargon and some abbreviations that I still have to google as a medical studentI could almost hear the chat's author scoff in judgement.

With the rise of electronic health records and ever-improving technology, one might be inclined to believe that these changes bring more benefit than harm to health care. While on the surface this might seem true, like everything else in our world, its not that simple. It means patients get significantly less time with doctors and feel more neglected than ever. It means people are living longer but with more chronic conditions. It means patient-centered care is being swapped for patient-centered charts. It means care providers are less focused on patients and more concerned with the bottom line.

As a result, they are suffering from more burnout than ever before. In fact, a 2018 survey by the Physicians Foundation found that six out of every 10 doctors surveyed (9,000 total) were either very or somewhat pessimistic about the future of the medical profession, citing electronic health record design and the patient-physician relationship for their marked dissatisfaction. In large part, this pervasive issue owes itself to shifts in medical culture from house calls and bedside manner in the early 1900s to 15-minute check-ins and a focus on profit margins in 2020.

Fortunately, however, not all health care professionals treat their patients and their bodies as medical specimens. Some physicians, like the neurologist I was shadowing, take the time to know their patientsand their familiesbeyond medical charts and insurance documentation. Because it can be difficult to mentally construct patients lives and narratives from the medical lingo of their charts, the doctor filled in the gaps for me that day. She gave life and meaning to abridged notes and otherwise apathetic paperwork. She told me about a young man who was likely taking his last breaths following a combined alcohol/cocaine/narcotics overdose.

While I was there, she was called to the ICU to examine him for the nth time in as many days. On the elevator ride up, she told me he was a college student who had been doing careless college student things. Her motherly disappointment was laced with a hint of sadness. I figured cases like these were commonplace for her, but it was humbling to see her humanness, especially since I didnt know what I was walking into that day. I wondered what it meant to be an overdose patient in a culture that was full of overmedicating, over-testing and over-charting, none of which offered an iota of humanity to a patient on the verge of death or a family nearing an irreplaceable loss.

She led me to her patients room in the ICU. He was no more than a year or two older than I was at the time. As I watched the ventilators help his limp body inhale and then exhale, I imagined he might have had a bright future ahead of him. I thought about the college party that allegedly landed him in this place. I wondered if he had been addicted or couldve been helped. I wondered who he would be leaving behind. I said a silent prayer for him as the doctor examined him, once again confirming a poor prognosis.

Quick footsteps approached. The doctor stepped into the hall to greet her patients mother. It became clear that his mother was just as much in need of the doctors warmth and care as he was. And because the neurologist was what I considered to be a good doctor, maybe even a rare one, she recognized it too. I listened as the doctor relayed a difficult prognosis. I watched the mother clutch her prayer beads so tightly her knuckles turned white. I learned that her son attended an Ivy League university and would be leaving behind a seemingly supportive and, at the moment, extremely distraught family. I know hell be okay she argued. She had seen him move. I remembered learning that overdose-related comas can result in elevated levels of motor activity due to the drugs effects on the brain stem. Contrary to what a hopeful mother might believe, this was not a reflection of consciousness or active motor reflexes.

The doctor, though she spoke matter-of-factly, delivered her professional opinion with patience and kindness. She was present for the mother. She understood that the lifeless young man in front of her was not just a body or another looming overdose death. He was someone with a family, a life that was worth living. She also saw a grieving mother before her who would soon have to make peace with this tragedy. Observing their interaction, I could see that most of the medical information the doctor shared flew past the womans ears. She was a mother, and she knew what she had seen; she fully believed that her son was on the cusp of waking up again. As a physician, the neurologist knew he wasnt going to get better; the damage was too far gone.

That day, I saw that ultimately it is not the language of science or evidence-based medicine that consoles real human beings facing real loss. It is not the objective medical gaze or microscopic view of the body as a specimen that provides comfort or reassurance. It is not the contrived form of empathy we are taught to show our patient-actors in our clinical skills courses that builds trust between doctors and their real patients. A scripted Oh, Im sorry to hear that. That must be so tough for you, only goes so far when youre caring for the sick and dying and their family members. In the end, the reality of medical practice and the doctor-patient relationship is about the impulse of being human, the vulnerability of being ill, and the process of healing, all of which we share in but so often forget in the process of becoming professionals.

But in this instance with the neurologist, I saw what it meant to look beyond a patients chart and to deviate from the feigned sympathy script of a medical school doctoring course. I saw a young man as a patient, a person with his own story; a mother in sorrow, no less a patient in that moment; and a doctor with oodles of knowledge standing quietly in solidarity with her patients mother. The neurologist reached her hand out and the mother graciously accepted her show of comfort, genuine and uncontrived. That, to me, is patient-centered care. Id be curious to see how a medical school might script that or how an electronic health record or insurance company might capture it for reimbursement.

Read the original:
What Does It Mean to Be a Good Doctor? - Scientific American

neurology services maine, stroke recovery maine, stroke …

Posted on by

Inland Neurology offers compassionate care for you and your loved ones. It is our goal to provide considerate, attentive care for the individual health needs of every patient. We believe in educating our patients with the best information we have, so that you can make the decisions that works best for you and your family.

Inland Neurology is a department of Inland Hospital. The practice is located at 246 Kennedy Memorial Drive, Suite 102, Waterville, Maine. Phone: (207) 861-7050. Inland is a proud member of EMHS.

Healthcare Services:Evaluation and treatment of neurological conditions including:

Office Hours:

Monday - 7:30 a.m. - 4:30 p.m.Tuesday - 7:30 a.m. - 4:30 p.m.Wednesday - 7:30 a.m. - 4:30 p.m.Thursday - 7:30 a.m. - 4:30 p.m.Friday - 7:30 a.m. - 4:30 p.m.

Appointments:Patients are seen by appointment with flexibility in our schedule to handle urgent medical cases.

In-House Services:

Financial Policies:

Here is the original post:
neurology services maine, stroke recovery maine, stroke ...

How Family in the Room Affects Patient Care – Medscape

Posted on by

Until recently, seriously ill people were often treated at home, surrounded by friends and family. As scientific advances have shifted medical care to the hospital, patients now rely on family visits for emotional support, and also for assisting with practical matters: helping with basic care, accessing old medical records, keeping track of medications. In my role as neurohospitalist at a county hospital, I have noticed another vital function of hospital visitors that is perhaps underappreciated: improving patient care.

I make daily hospital rounds with a neurology resident and occasionally medical students. Rounds are always hurried; we must examine every patient, review neuroimaging and laboratory results, discuss cases with consultants, and document everything in the cumbersome electronic medical record. We explain as much as we can to patients and their families.

However, many patients are alone with minimal, if any, ability to communicate. Often, neurology patients are encephalopathic or comatose, limiting our interaction. Some are homeless or have poorly controlled mental illness. The patient may be a "John Doe" whose true name is unknown. No visitors will arrive until administrators identify the patient. Demented elderly patients, many of whom have lost a lifelong partner, may also endure hospitalizations alone. In all these situations, without family to communicate with, my time in the room may be brief. Sometimes patients remain alone and incommunicado for days.

A concerned family also holds me to account.

The persistent absence of visitors seems to convey a silent message: "In the outside world, no one cares about me." Although visitors may not be in attendance for many reasonswork obligations, distance, lack of knowledge of the hospitalization, or even an independent patient's wishesan empty room advocates poorly for the patient.

Face-to-face time with each patient varies depending upon many factors, especially the complexity of the case and the clarity of the diagnosis. When family members are present, I take additional time to explain the diagnosis, prognosis, and therapeutic plan.

Sometimes that extra time improves the patient's care. It provides space for a more thorough exploration of the case and for consideration of fresh diagnostic and therapeutic options. Extra minutes may solidify a nascent therapeutic alliance. A concerned family also holds me to account, elevating the patient's importance in my mind.

Of course, longer patient visits aren't necessarily better visits. Families can be distracting when their needs and behavior pull focus from the patient.

But I often thank visitors for their presence and assistance. Many must sacrifice much needed income by taking leave from work, cope with unexpected travel expenses, or otherwise place their lives on hold. I have walked in those shoes and it is not easy.

Lately, after examining a patient alone in his or her room, I pause for a few seconds. I methodically wash my hands and thoroughly dry them with a paper towel. I scan the monitors. I watch the patient breathe. I let my thoughts settle.

Then I mentally explain the case to a nonexistent family member. Although patients cannot participate, they bear witness to these silent conversations. It's my hope that this additional attention improves their care. Maybe someday one of my patients will tell me.

Andrew Wilner is a professor of neurology at the University of Tennessee Health Science Center in Memphis, a health journalist, and an avid SCUBA diver. His latest book is The Locum Life: A Physician's Guide to Locum Tenens.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the original post:
How Family in the Room Affects Patient Care - Medscape

Global Minimally Invasive Neurology Device Market Demand Analysis, Development Factors, Overview with Manufacturers And Forecast 2026 – News Times

Posted on by

The report specifies the Global Minimally Invasive Neurology Device Market share held by the significant players of the business and conveys a full perspective on the focused scene. The market is ordered into various sections with the complete examination of each concerning the topography for the investigation time frame. The report has turned the spotlight on the startling rise in verifiable investigation and evaluations in the Minimally Invasive Neurology Device market with its future prospects.

This research focus on Top-down and Bottom-up research analysis progression, which will help investors to analyze the financial market and to perform desired operations to choose Minimally Invasive Neurology Device market investments in the forthcoming year 2020-2026.

Get a Sample copy of Minimally Invasive Neurology Device research report which will assist you to make better business decisions. [emailprotected] https://www.reportspedia.com/report/life-sciences/global-minimally-invasive-neurology-device-market-report-2019,-competitive-landscape,-trends-and-opportunities/28292 #request_sample

Key Players:

Mayo Clinic CompanySwedish Neuroscience Institute CompanyNICO Corporation CompanyXylos CorporationMedtronic plcTel Aviv Sourasky Medical Center CompanyHadassah Medical Center CompanyReplication Medical, Inc.StereoTools SAOptiscan Imaging Limited Company

Conformed by Reportspedia.com Research, the Minimally Invasive Neurology Device market has been predicted to expand at a growth rate during the forecasting years of 2020-2026, driven by various factors. For instance, the development of the market has been very crucial for the advancement of the Minimally Invasive Neurology Device market globally.

Minimally Invasive Neurology Device Market Competitive Analysis

The research report helps to identify business competitors and helps to evaluate their business strategies to define the key players strengths and weaknesses associated with the products and services offered by manufacturing industries. Competitive analysis is a critical process to identify Minimally Invasive Neurology Device competitors marketing plan, to attract your target market Reportspedia.com has provided analytical data, which contain graphs, charts, and business values to create unique product or services in the global market. It includes a brief analysis of Minimally Invasive Neurology Device industry competitors, competitors global and regional sell, competitors market share, past and current strategies, type of media to market product or services, and potential openings.

The Minimally Invasive Neurology Device Market has been categorized in the report :

Types:

Type 1Type 2Type 3

Applications:

Application 1Application 2Application 3

Want To Institute Strategies For Upcoming Years? Our Reports Can Assist You To Plot Superior. Inquire Here : https://www.reportspedia.com/report/life-sciences/global-minimally-invasive-neurology-device-market-report-2019,-competitive-landscape,-trends-and-opportunities/28292 #inquiry_before_buying

Regions:

South America Minimally Invasive Neurology Device Market Covers Colombia, Brazil and Argentina

North America Market Covers United States, Canada and Mexico

Europe Minimally Invasive Neurology Device Market Covers UK, Germany, Italy, France and Russia

The Middle East and Africa Market Covers Saudi Arabia, Egypt, South Africa, UAE and Nigeria

Asia Pacific Minimally Invasive Neurology Device Market Covers Korea, India, Japan, Southeast Asia and China

Key questions answered in this report:

Contents of the 12 Chapter for Global Minimally Invasive Neurology Device Market Study:

Section 1: Describe Minimally Invasive Neurology Device Market Introduction, detail scope, market review, market availabilities, market risk, market-main drive;

Section 2: To break down the best producers, with Sales, income, and cost of Market;

Section 3: To show the aggressive circumstance among the best producers, with Sales, income and Minimally Invasive Neurology Device market share in 2019;

Section 4: To demonstrate the Global market by regions, with sales, income, and offers for every area;

Section 5, 6, 7, 8 and 9: To break down the key districts, with Sales, income and Minimally Invasive Neurology Device market share by key nations in these areas;

Section 10 and 11: To demonstrate the Minimally Invasive Neurology Device market by type and application, with sales market suggestion and development rate by 2026;

Section 12: market conjecture, by locales, type, and application, with sales and income, from 2019 to 2026;

Ask for Detailed TOC of the Report. [emailprotected] : https://www.reportspedia.com/report/life-sciences/global-minimally-invasive-neurology-device-market-report-2019,-competitive-landscape,-trends-and-opportunities/28292 #table_of_contents

Finally, all the fragments have been dependent on present and future patterns and the Minimally Invasive Neurology Device market is assessed from 2020 to 2026.

Thanks a bunch for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. [emailprotected]

Read more here:
Global Minimally Invasive Neurology Device Market Demand Analysis, Development Factors, Overview with Manufacturers And Forecast 2026 - News Times

Oncology & Neurology Disorder Drugs Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 – News Times

Posted on by

Global Oncology & Neurology Disorder Drugs Market 2019 by key players, regions, type, and application, forecast to 2026. Oncology & Neurology Disorder Drugs Market Report contains a forecast of 2019 and ending 2026 with a host of metrics like supply-demand ratio, Oncology & Neurology Disorder Drugs Market frequency, dominant players of Oncology & Neurology Disorder Drugs Market, driving factors, restraints, and challenges. The report also contains market revenue, sales, Oncology & Neurology Disorder Drugs production and manufacturing cost that could help you get a better view of the market. The report focuses on the key global Oncology & Neurology Disorder Drugs manufacturers, to define, describe and analyze the sales volume, value, market competition landscape, market share, SWOT analysis and development plans in future years.

Download Free Sample Copy of Oncology & Neurology Disorder Drugs Market Report: https://dataintelo.com/request-sample/?reportId=44608

The report provides information on trends and developments and focuses on market capacities, technologies, and the changing structure of the Oncology & Neurology Disorder Drugs Market . The new entrants in the Oncology & Neurology Disorder Drugs Market are finding it hard to compete with the international dealer based on quality and reliability.

Major Players included in this report are as follows ProStrakanPacira PharmaceuticalsAbbottGlaxoSmithKlineTranscept PharmaceuticalsArchimedes

Oncology & Neurology Disorder Drugs Market can be segmented into Product Types as Product Type IProduct Type IIProduct Type III

Oncology & Neurology Disorder Drugs Market can be segmented into Applications as Application IApplication IIApplication III

Oncology & Neurology Disorder Drugs Market: Regional analysis includes: Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Buy the full version of this report at: https://dataintelo.com/checkout/?reportId=44608

Influence of the Oncology & Neurology Disorder Drugs Market report: Comprehensive assessment of all opportunities and risk in the Oncology & Neurology Disorder Drugs Market. The Oncology & Neurology Disorder Drugs Market recent innovations and major events. A detailed study of business strategies for growth of the Oncology & Neurology Disorder Drugs Market-leading players. Conclusive study about the growth plot of Oncology & Neurology Disorder Drugs Market for forthcoming years. In-depth understanding of Oncology & Neurology Disorder Drugs Market-particular drivers, constraints and major micro markets. Favourable impression inside vital technological and market latest trends striking the Oncology & Neurology Disorder Drugs Market.

Objective of Studies: 1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Oncology & Neurology Disorder Drugs Market. 2. To provide insights about factors affecting the market growth. To analyse the Oncology & Neurology Disorder Drugs Market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc. 3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World. 4. To provide country level analysis of the market with respect to the current market size and future prospective. 5. To provide country level analysis of the market for segment by application, product type and sub-segments. 6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market. 7. To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Oncology & Neurology Disorder Drugs Market.

Customize Report and Inquiry for The Oncology & Neurology Disorder Drugs Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=44608

The huge assortment of tables, graphs, diagrams, and charts obtained in this market research report generates a strong niche for an in-depth analysis of the ongoing trends in the Oncology & Neurology Disorder Drugs Market. Further, the report revises the market share held by the key players and forecast their development in the upcoming years. The report also looks at the latest developments and advancement among the key players in the market such as mergers, partnerships, and achievements.

In short, the Global Oncology & Neurology Disorder Drugs Market report offers a one-stop solution to all the key players covering various aspects of the industry like growth statistics, development history, industry share, Oncology & Neurology Disorder Drugs Market presence, potential buyers, consumption forecast, data sources, and beneficial conclusion.

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

See more here:
Oncology & Neurology Disorder Drugs Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 - News Times

Retired Calgary neurologist pleads guilty to dozens of sexual assaults dating back to 1980s – The Globe and Mail

Posted on by

A retired neurologist has admitted in court to sexually assaulting 28 female patients over three decades.

Keith Hoyte, 71, pleaded guilty to 28 counts as his trial was to begin Monday in Calgary. Two counts were stayed because they were melded into charges involving the same victims.

Crown prosecutor Rosalind Greenwood read aloud an agreed statement of facts describing how victims between 17 and 46 felt confused, embarrassed, numb and angry during appointments with Dr. Hoyte.

Story continues below advertisement

The common thread running through the evidence is that Dr. Hoyte was seeking, in each instance, to obtain sexual gratification from his patients, the statement said.

The charges relate to assaults between 1983 or 1984 to 2013.

In the statement, women described being told to undress from the waist up, even though they were there seeking treatment for brain ailments, such as migraines and seizures.

They described Dr. Hoyte fondling their breasts and pricking them with pins, while the doctor made little eye contact or conversation. In some cases, he pushed down gowns without his patients consent.

Court heard that most of the time he did not explain what he was doing or why. In others, he said it was to test reflexes or sensation.

One woman described how Dr. Hoyte instructed her to walk back and forth with her eyes closed, arms outstretched and her gown wide open. She opened her eyes to see him crouching down and looking under the gown. He then grabbed her breast and pushed his body against her, the agreed statement of facts said.

As she left the appointment, she said to herself, What the heck just happened?'" the document said.

Story continues below advertisement

She tried to rationalize what happened. She also thought about reporting the incident, but thought to herself, Whos going to believe me? It would be my word against his.'"

That woman, trusting a family doctor who made the referral, went to see Dr. Hoyte for another appointment six years later, during which he tugged down her gown so hard she could hear the stitching rip, she recalled.

One victim went to police in 1991, one in 2008 and another in 2018. Police charged Dr. Hoyte with three counts of sexual assault in June 2018. After media reports, 25 more women came forward.

Complainants gave varied reasons for not reporting Dr. Hoyte sooner. Many thought they wouldnt be believed. One didnt want to be thought of as a difficult patient when it was so hard to get a referral. Another one had debilitating headaches and she didnt want to risk not getting some answers.

Another young woman recounted staring at her pointy fuchsia shoes during the appointment thinking: Let this end.

The 19-year-old recalled how, when she tried to push his hands away from her breasts, the doctor became angry.

Story continues below advertisement

The look on his face told it all, she said, according to the agreed statement of facts. She recalled saying she was done and leaving the office in tears.

Submitted with the agreed statement of facts was a report from another doctor who said there is no legitimate clinical explanation for what Dr. Hoyte did during the examinations.

The case is next in court Jan. 17 to set a date for sentencing. Defence lawyer Alain Hepner has requested a psychological risk assessment.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the days most important headlines. Sign up today.

Go here to see the original:
Retired Calgary neurologist pleads guilty to dozens of sexual assaults dating back to 1980s - The Globe and Mail

Edited Transcript of ALXN earnings conference call or presentation 30-Jan-20 12:30pm GMT – Yahoo Finance

Posted on by

CHESHIRE Feb 5, 2020 (Thomson StreetEvents) -- Edited Transcript of Alexion Pharmaceuticals Inc earnings conference call or presentation Thursday, January 30, 2020 at 12:30:00pm GMT

Alexion Pharmaceuticals, Inc. - Executive VP & CFO

* Brian M. Goff

Alexion Pharmaceuticals, Inc. - Executive VP & Chief Commercial and Global Operations Officer

* John J. Orloff

Alexion Pharmaceuticals, Inc. - Executive VP and Head of Research & Development

* Ludwig N. Hantson

Alexion Pharmaceuticals, Inc. - CEO & Director

SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst

Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

* Kennen B. MacKay

RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

Ladies and gentlemen, thank you for standing by. And welcome to the Alexion Pharmaceuticals Fourth Quarter and Full Year 2019 Results Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded.

I would now like to hand the conference over to Morgan Sanford, Director, Investor Relations. Please go ahead, ma'am.

Thank you, operator. Good morning. Thank you for joining us on today's call to discuss Alexion's performance for the fourth quarter and full year 2019.

Today's call will be led by Ludwig Hantson, our CEO. Ludwig will be joined by Aradhana Sarin, our Chief Financial Officer; John Orloff, our Global Head of R&D; and Brian Goff, our Chief Commercial and Global Operations Officer.

You can access the webcast slides that will be presented on this call by going to the Events section of our Investor Relations page on our website.

Before we begin, I would like to point out that we will be making forward-looking statements, and these statements involve certain risks and uncertainties that could cause our actual results to differ materially. Please take a look at the risk factors discussed in our SEC filings for additional detail.

These forward-looking statements apply only as of today, and we undertake no duty to update any of the statements after the call, except as required by law.

I'd also like to remind you that we will be using non-GAAP financial measures, which we believe provide useful information for the understanding of our ongoing business performance. Reconciliations of our financial results and financial guidance are included in our press release. These non-GAAP financial measures should be considered, in addition to but not as a substitute for our GAAP results.

Thank you. Ludwig?

Ludwig N. Hantson, Alexion Pharmaceuticals, Inc. - CEO & Director [3]

Thank you, Morgan, and good morning, everyone. Before we review our fourth quarter and 2019 full year performance, I would like to take a brief moment to announce that we have successfully closed on our acquisition of Achillion Pharmaceuticals, which represents an important step in diversifying our business. Through this acquisition, we add 2 clinical stage assets to our portfolio with danicopan and 5228. We are thrilled to welcome our Achillion colleagues to Alexion and excited about the opportunity to collaborate on the development of these Factor D assets for a broad range of rare diseases.

Turning now to our 2019 performance. We delivered on all of our key objectives, and in many cases, have surpassed our goals. ULTOMIRIS is now the market leader in PNH in our 3 largest markets: the U.S., Germany and Japan. The ULTOMIRIS' aHUS conversion is progressing well in the U.S. and we anticipate launching in the EU and Japan this year. We are also very pleased with the uptake of our neurology franchise, with continued growth of SOLIRIS and gMG and the launch in NMOSD. In just over 2 years, neurology has become our largest franchise in the U.S. by patient volumes. Our ambition is to quadruple the number of MG and NMOSD patients treated by SOLIRIS and eventually ULTOMIRIS in the U.S. by 2025.

Our metabolics portfolio continues to deliver strong growth as we work to expand access for HPP, LAL-D patients. Importantly, we have made great progress on our pipeline, and have an ambition for 10 launches from now until the end of 2023 through a combination of new assets, new formulations and new indications, and once again, have delivered on our financials with 21% revenue growth and 33% non-GAAP earnings growth in 2019.

Turning to Slide 6. We have a clear strategy for long-term value creation. First, we will move past SOLIRIS and establish ULTOMIRIS as market leader in PNH and aHUS in our 3 key geographies. Secondly, we will expand our C5 franchise beyond PNH and aHUS into larger rare diseases. We have ULTOMIRIS programs planned in 6 new indications, including 4 neurology and 2 nephrology indications. In parallel, we will continue to innovate with patients with new formulations and subcu treatment options.

Finally, we will diversify our portfolio beyond C5. Achillion is the most recent example of this effort. With Factor D, we have the opportunity to pursue development in a broad range of indications. Outside of this transaction, we have built a robust rare disease pipeline over the past few years and have clear line of sight to multiple potential blockbuster launches, including treatments for Wilson disease and AL amyloidosis. We have significant financial capacity to continue to diversify our pipeline in the future.

In addition to bringing in external assets to diversify our business, we are evolving our leadership in complement to expand our addressable patient population.

On Slide 7, you can see our business is rapidly moving beyond SOLIRIS. ULTOMIRIS is approved for 2 indications.

(technical difficulty)

This is Ludwig Hantson again. We had a technical issue. I hope that you guys can hear us okay. So what I will do is instead of restarting, we're going to start on Slide 6, and then we'll take it from there.

So turning to Slide 6. We have a clear strategy for long-term value creation. First, we will move past SOLIRIS and establish ULTOMIRIS as market leader in PNH and aHUS in our 3 key geographies. Secondly, we'll expand our C5 franchise beyond PNH and aHUS into larger rare diseases. We have ULTOMIRIS programs planned in 6 new indications, including 4 neurology and 2 nephrology indications. In parallel, we will continue to innovate for patients with new formulations and subcu treatment options.

Finally, we will diversify our portfolio beyond C5. Achillion is the most recent example of this effort. With Factor D, we have the opportunity to pursue development in a broad range of indications. Outside of this transaction, we have built a robust rare disease pipeline over the past few years and have clear line of sight to multiple potential blockbuster launches, including treatments for Wilson disease, and AL amyloidosis. We have significant financial capacity to continue to diversify our pipeline in the future.

In addition to bringing in external assets to diversify our business, we are evolving our leadership in complement to expand our addressable patient population.

On Slide 7, you can see our business is rapidly moving beyond SOLIRIS. ULTOMIRIS is approved for 2 indications and in development for 6 additional indications across neurology and nephrology. This year, we will transition to a high concentration formulation, which will shorten infusions to only 45 minutes. Next year, we plan to launch our once-weekly, on-body, subcu ULTOMIRIS formulation, offering patients a home-based self-administration option.

Our next-generation subcu assets, 1810 and 1720, offer improved patient dosing regimens. And we have significant optionality for indication selection with each of these assets. From there, we will expand with Achillion's Factor D platform. We see immense opportunity for all proximal complement treatments to transform standard of care in many complement-mediated diseases.

On Slide 8, you see that once again, we have delivered strong top and bottom line growth for the fourth quarter and the full year, which provides a solid foundation to continue to deliver on our value creation strategy. Again, I'm very pleased with our strong execution against our 2019 priorities and excited for 2020 as we build on our successes.

With that, I will now turn the call over to Rana.

--------------------------------------------------------------------------------

Aradhana Sarin, Alexion Pharmaceuticals, Inc. - Executive VP & CFO [4]

--------------------------------------------------------------------------------

Thank you, Ludwig. Starting with Slide 10, we reported fourth quarter total revenues of approximately $1.4 billion, an increase of 23% year-over-year. This was driven by strength in our neurology franchise, continued growth in the core businesses and ULTOMIRIS launch. Our non-GAAP operating margin was 51%, a reduction of 155 basis points versus prior year, driven by increased R&D spend as we advanced and further build our development portfolio. Non-GAAP EPS was $2.71, representing 27% growth year-over-year, driven primarily by strong top line growth and lower effective tax rate.

Moving to Slide 11. Fourth quarter total net product sales were primarily driven by patient volume growth in our key markets.

Turning to Slide 12. SOLIRIS revenues in the fourth quarter were approximately $1 billion, with year-over-year growth of 4%. SOLIRIS revenue growth was driven primarily by gMG revenues, partially offset by ULTOMIRIS' conversion dynamics. ULTOMIRIS revenues in the fourth quarter were $170 million, which now includes contributions from atypical HUS in the United States.

Metabolics revenues in the fourth quarter were $201 million, representing 32% year-over-year growth.

Turning to the P&L, on Slide 13. During the quarter, non-GAAP R&D expense was $227 million or 16% of revenues. Non-GAAP SG&A expense was $340 million or 25% of revenues. The non-GAAP effective tax rate in the quarter was approximately 12% and continued to benefit from certain onetime events, including the release of state income tax reserves related to the conclusion of an audit.

We reported fourth quarter non-GAAP EPS of $2.71, growing 27% year-over-year. GAAP earnings per share were $4. We ended the fourth quarter with approximately $2.7 billion in cash and marketable securities. This is not adjusted for the Achillion transaction.

I'll now turn to Slide 14 for our 2020 financial guidance. We are guiding to total revenues between $5.5 billion and $5.56 billion. This represents 11% growth year-over-year at the midpoint of the range. For SOLIRIS and ULTOMIRIS, our revenue guidance is $4.755 billion to $4.800 billion. This assumes continued momentum for SOLIRIS in gMG, our ongoing launch of SOLIRIS in NMOSD and the launches of ULTOMIRIS for PNH and atypical HUS.

Turning to metabolics. Our revenue guidance is $745 million to $760 million for both STRENSIQ and KANUMA. This includes the impact of the strategic pricing decision for STRENSIQ in the U.S. to support sustainability and access given weight-based dosing.

In 2020 and beyond, it is important to consider the dynamics associated with conversion from SOLIRIS to ULTOMIRIS, as it relates to the annual cost per patient. There's a revenue benefit when each patient starts ULTOMIRIS' PNH treatment due to the increased number of vials consumed during the loading dose. We benefited from this loading dose dynamic having converted 60-plus percent of patients in PNH to ULTOMIRIS over the course of 2019. We now expect to be impacted by lower annual treatment cost per patient, as the majority of patients move to maintenance dosing.

In atypical HUS and other indications in development, we will see a lower annual cost per patient compared to SOLIRIS for both loading dose and maintenance dosing. It is also important to consider quarter-over-quarter variability due to every 8-week dosing for ULTOMIRIS. However, this quarterly fluctuation will even out on an annual basis.

We have included a slide in the Appendix of this presentation to provide a summary of this dynamic and to serve as a reference going forward.

Non-GAAP operating margin is expected to be between 53.5% and 54.5% of revenues. Non-GAAP R&D expense is expected to be between 17.5% and 18.5% of revenues and represents a step-up of approximately $270 million versus prior year, consistent with our intention to further build out and progress the pipeline.

Clinical program spend, particularly for late-stage development, is planned to increase in 2020. R&D expense also includes program costs and potential milestones for previously-announced BD transactions and collaborations.

Non-GAAP SG&A spend is expected to be between 19.5% and 20.5% of revenues for the full year 2020 and reflects increased leverage from top line growth. We expect the non-GAAP effective tax rate to be between 16% and 17%.

In 2019, the non-GAAP effective tax rate benefited from certain onetime items. Absent these onetime benefits, our 2019 non-GAAP tax rate would have been approximately 15%. We expect our non-GAAP effective tax rate to increase in the future as a result of tax regulation changes outside the U.S.

GAAP EPS is expected to be between $7.91 and $8.71. Non-GAAP EPS is expected to be between $10.65 and $10.85. The midpoint of the non-GAAP EPS is approximately 2% growth year-over-year as a result of increased R&D spend and an increased tax rate compared to prior year. This guidance reflects the financial impact of our recently closed Achillion acquisition, but does not reflect any future M&A that we may pursue.

As you can see on Slide 15, we have established a track record of strong financial execution. Since 2017, we have delivered double-digit total revenue and non-GAAP EPS growth, while maintaining a competitive non-GAAP operating margin. We continue to invest in our R&D programs and have increased our non-GAAP R&D spend as a percentage of revenues to within 16% to 19%, in line with our biotech peers. With the current momentum of the business, we are well positioned to deliver on our 2020 financial goals.

I'll now turn the call over to John to provide an update on R&D.

--------------------------------------------------------------------------------

John J. Orloff, Alexion Pharmaceuticals, Inc. - Executive VP and Head of Research & Development [5]

--------------------------------------------------------------------------------

Thank you, Aradhana. On Slide 17, you can see our current development portfolio. We now have 19 planned clinical stage development programs for 2020. In the coming weeks and months, we expect to report interim data from our Phase III once-weekly, on-body, subcutaneous ULTOMIRIS program; an update on our anti-FcRn studies; and interim data from the Phase II study of danicopan and C3G. We're excited about the acquisition of Achillion and look forward to providing additional detail in the coming months as we embark on the integration.

Just a few weeks ago, we reiterated our ambition to execute 10 launches by 2023 from our current portfolio. On Slide 18, you can see our R&D highlights, which summarized these programs, including stage in clinical development and the estimated addressable population. We are expanding our C5 presence well beyond the PNH and atypical HUS business and are advancing ULTOMIRIS into 5 additional indications across neurology and nephrology. Together, the ULTOMIRIS programs present an opportunity to expand our treated patient population by tens of thousands of patients. We believe in the compelling value proposition of ULTOMIRIS, which has been received well by patients, physicians and other key stakeholders, and are continuing to innovate with a high-dose concentration, reducing infusion time to 45 minutes and a once-weekly, on-body ULTOMIRIS subcutaneous formulation.

In addition to ULTOMIRIS indication expansion programs, we see opportunity to diversify our business beyond C5, with 4 additional late-stage novel assets. Our Phase III Superiority Trial for ALXN1840 in Wilson's disease remains ongoing. 1840 is an oral, once-daily therapy, with 10,000-fold higher affinity for copper than current standard of care chelators, which have core compliance rates due to burdensome dosing regimens. We're on the verge of completing enrollment and expect a top line readout in the first half of next year.

We plan to initiate a Phase II/III program for CAEL-101 in AL amyloidosis in the coming months. We see potential for this late-stage asset to transform the treatment of AL amyloidosis, a disease characterized by misfolded kappa and lambda light chains, resulting in abnormal deposits of amyloid, which can lead to organ failure. Patients are currently treated with chemotherapeutic agents not approved for amyloidosis, and median survival rates are only 18 months post-diagnosis.

Clinical data supporting our rationale for the collaboration showed a 63% overall organ response rate in addition to efficacy on cardiac and renal endpoints. Our Phase II/III program will look at an overall survival primary endpoint with patient function, quality of life and cardiac imaging serving as secondary endpoints.

Last year, we announced a license agreement with Eidos, to develop and commercialize AG10 for ATTR cardiomyopathy in Japan. AG10 is a small molecule designed to address destabilized and misfolded transthyretin protein, which is the root cause of ATTR. We believe AG10 has potential to stabilize TTR and halt disease progression. Pending regulatory discussions, we plan to extend the AG10 development program into Japan later this year.

Finally, we are excited about our acquisition of Achillion and its Factor D platform. Achillion reported positive Phase II data for danicopan in PNH patients with extravascular hemolysis at a medical conference last year. We see opportunity for danicopan in a small subset of PNH patients with extravascular hemolysis. We see additional opportunity for danicopan and C3G, and expect interim Phase II data in the coming weeks, and we see great potential for ACH-5228, as twice daily, best-in-class Factor D oral treatment in PNH and a broad range of rare diseases.

We are excited about the opportunity for these 10 potential launches to significantly expand the number of treated patients and look forward to providing you with updates as we progress through the year.

Moving to Slide 19. We have plans to further expand and diversify our C5 leadership with our next-generation assets. Starting on the left, our weekly subcutaneous formulation of ULTOMIRIS for use in PNH and atypical HUS is in an ongoing Phase III PK-based trial. Leveraging the West Gen on-body device, we believe this will provide patients with the flexibility to choose how they wish to manage their disease within their lifestyle. We are expecting interim PK data in the second quarter of this year with a potential launch in 2021.

Next, we have the opportunity to evolve our terminal complement subcutaneous treatment options with ALXN1720 and 1810. 1720 is our internally-designed bi-specific C5 inhibitor. At only 25 kilodaltons, 1720 is a unique mini-body tailor-made for convenient subcutaneous administration. We see opportunity for this asset in a number of larger rare disease indications, and we look to initiate a proof-of-concept study in the first half of next year.

Finally, 1810 is our co-formulation of ULTOMIRIS in Halozyme's PH20 hyaluronidase, which allows for biweekly subcutaneous dosing. We've recently disclosed our plans to start a Phase II renal basket trial with 1810 and look forward to providing additional updates as this program progresses.

Together, these 3 assets represent an opportunity for Alexion to expand our offerings for patients living with complement-mediated rare disease. Our development portfolio has grown significantly in the last 2.5 years, and I'm incredibly proud of all the hard work undertaken by the entire R&D organization.

With that, I'll turn the call over to Brian to provide commercial highlights for the quarter. Brian?

--------------------------------------------------------------------------------

Brian M. Goff, Alexion Pharmaceuticals, Inc. - Executive VP & Chief Commercial and Global Operations Officer [6]

--------------------------------------------------------------------------------

Thank you, John. Turning first to Slide 22. We've seen unprecedented progress in establishing ULTOMIRIS as the market leader in PNH. This is due in large part to the compelling value proposition, which includes strong data from the largest and most inclusive PNH clinical program ever conducted. The broad inclusion criteria in the 2 Phase III trials ensure their study patient population would be representative of the real-world PNH population.

Specifically, we enrolled transfusion-independent and transfusion-dependent patients, with no baseline hemoglobin or absolute reticulocyte count requirements. We also included patients with prior history of bone marrow failure, which is critical because roughly 40% to 50% of PNH patients have a history of bone marrow failure or aplastic anemia.

As of Monday of this week, we've converted 60% of PNH patients to ULTOMIRIS in the U.S., 62% in Germany and 53% in Japan, making ULTOMIRIS the PNH market leader in our 3 largest volume countries.

Our latest launch of ULTOMIRIS in atypical HUS in the U.S. is also off to a strong start. While it's still early days, conversion is tracking in line with the PNH conversion curve at the same time point since launch.

Our neurology business is now our largest franchise by patient volume, and this was achieved in just 2 years since launch. On Slide 23, you can see we exited the fourth quarter with 1,885 patients on treatment with SOLIRIS for gMG and NMOSD in the U.S. We've made significant progress advancing our presence in gMG and with our NMOSD launch. gMG patients continue to have broad access to SOLIRIS. Our strong NMOSD launch is underpinned by our remarkable Phase III data, showing 98% of patients relapse-free at 48 weeks, with sustained efficacy out to 3 years. We're making progress educating payers on the severity of NMOSD attacks, the objective of preventing all relapses and the difference between NMOSD and MS. As a result of these efforts, payer adoption of coverage policies for NMOSD has been rapid, and we're seeing strong adherence to SOLIRIS therapy in both gMG and NMOSD.

Looking ahead, we're well positioned to deliver on our ambition of quadrupling our U.S. gMG and NMOSD-treated patient population within the next 5 years, with potential for ULTOMIRIS to launch in late 2022 or early 2023 as an every 8-week infusion. Our once-weekly, on-body subcutaneous formulation plan to launch simultaneously with the IV formulation will provide another important treatment option for patients who prefer self or home-based administration.

Our target gMG population represents more severe, uncontrolled patients, and we believe this is a unique space where SOLIRIS, and then ULTOMIRIS, can serve as a highly effective treatment option. In NMOSD, our target patient population mirrors inclusion criteria in our Phase III SOLIRIS PREVENT trial. With our dedicated neurology team, we believe our commercial organization is well positioned to deliver on our 2025 ambitions.

I'd like to take a brief moment to thank both our global commercial and global operations organizations for their hard work and dedication, which has enabled us to excel with multiple launches and continue to bring hope to the rare disease patients we serve.

I'll now turn the call back to Ludwig for closing comments. Ludwig?

--------------------------------------------------------------------------------

Ludwig N. Hantson, Alexion Pharmaceuticals, Inc. - CEO & Director [7]

--------------------------------------------------------------------------------

Thank you, Brian. Once again, I'm very proud of what the team delivered in 2019. We're well positioned to further build on our momentum in 2020, and there is much to look forward to this year. We have laid out a clear strategy to deliver long-term shareholder value by establishing ULTOMIRIS as market leader in PNH and aHUS, expanding our presence in C5, including planned programs in neurology and nephrology and continue to look for opportunities to diversify our business beyond C5.

Importantly, we maintain our unwavering focus on patients and our commitment to advance our mission to deliver life-changing therapies to people living with rare diseases.

With that, we will now open the call to questions. Operator?

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from Cory Kasimov of JPMorgan.

--------------------------------------------------------------------------------

Follow this link:
Edited Transcript of ALXN earnings conference call or presentation 30-Jan-20 12:30pm GMT - Yahoo Finance

AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis – BioSpace

Posted on by

Illinois-based AbbVie and La Jolla, California-based The Scripps Research Institute entered into a broad research collaboration in oncology, immunology, neurology and fibrosis.

Based on our strong switchable CAR-T alliance launched in 2018, we feel the expanded relationship with AbbVie represents a robust path forward for some of our programs, complementing a diverse ecosystem of innovation weve created over the past several years at Scripps to advance life-changing therapies, said Peter Schultz, chief executive officer of Scripps Research and Calibr, its drug discovery division.

Under the terms of the 2018 agreement, AbbVie paid Calibr an upfront license fee and picked up exclusive access to Calibrs switchable CAR-T platform for up to four years. The plan was to develop T-cell therapies against solid tumor targets chosen by AbbVie. AbbVie had the option to develop more cell therapies toward its targets and license existing Calibr cell therapy programs in hematological and solid cancers, including Calibrs lead programs.

In the new collaboration, in addition to the initial programs, Scripps will offer AbbVie a certain number of preclinical programs each year to be included in the partnership. They will work together in parallel to advance CD3 bispecifics against cancer targets picked by AbbVie

Under the terms of the deal, Scripps will run preclinical R&D, and in some cases, Phase I clinical trials. AbbVie will have an exclusive option to continue development and possible commercialization activities.

Once AbbVie chooses to exercise its option on any given program, it will pay Scripps additional payments that include option exercise fees, success-based development and commercial milestone payments, and tiered royalties. At hitting a milestone, AbbVie will make an undisclosed upfront payment as well as near-term milestone payments.

The best way to develop transformational medicines is through collaborations that bring together the brightest minds, said Mohit Trikha, vice president and head of oncology early development at AbbVie. This partnership with Scripps Research will collaboratively advance next generation programs, build stronger relationships with proven and emerging scientific leaders, and most importantly help us advance novel medicines for patients.

Trikha added, We are eager to partner with Scripps on these assets as they enter the clinic over the next few years as Scripps has one of the strongest track records of any academic institution when it comes to advancing novel medicines for patients.

Although neither organization released financial terms, they did say the partnership requires antitrust review. Under the law, reports The San Diego Union-Tribune, antitrust review has to be conducted for deals exceeding $84.4 million.

The Tribune notes, A deal of that size will bolster the La Jolla biomedical science institutes troubled finances for several years, and perhaps much longer. And if approved cancer therapies result, the payout could be gigantic.

The early work will be on an immuno-oncology treatment for lymphoma, which Calibr plans to launch in the clinic in 2020.

What were developing is a fully controllable, universal switchable CAR-T cell platform that allows a physician fine control over the activation and specificity of the CAR-T cells, Travis Young, director of protein sciences at Calibr told The Tribune.

At the moment, there are two CAR-T products approved, Novartis Kymriah and Gilead Sciences Yescarta. Both are quite effective in certain patient populations, but the process is expensive and time-consuming, requiring immune cells be collected from the patient, engineered to focus on the patients specific cancer, then be infused back into the patient. A number of companies are working on off-the-shelf CAR-T, that would not require the specific engineering catered to each patient.

CAR-T and other immunotherapy approaches also have high risks of immune reactions, although Novartis and Gilead have both developed protocols for minimizing or dealing with them. Scripps argues that their type of CAR-T improves over these, particularly in terms of safety, convenience and versatility.

These antibody-based switches bridge the CAR-T cells to the target cell. And so, by forming that bridge, they develop an immunological synapse, which redirects the CARs very specifically towards the target cells, said Young.

They also claim they can control the intensity of the response by varying the number of antibodies infused, would should minimize the adverse immune reactions.

The Tribune notes that in recent years Scripps has reported annual deficits that have hit as high as $20 million. The company currently has a drug in early clinical trials for osteoarthritis and is prepping another for prostate cancer, which it is hoping to partner with a company for commercialization.

See original here:
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis - BioSpace

Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio(TM) -…

Posted on by

SANTA CLARA, Calif., Jan. 9, 2020 /PRNewswire/ --Based on its recent analysis of the North American essential tremor (ET) treatment market, Frost & Sullivan recognizesCala Health, Inc.with the 2019 North American Technology Innovation Award for its Cala Trio, a prescription-only, wrist-worn device. This non-invasive, patient-friendly therapy causes minimal side-effects and is more cost-effective than current ET treatment methods. The on-demand electrical stimulation is based on the individual tremor patterns, and takes personalized therapy to the next level. ET is the most prevalent tremor disorder and one of the most common neurological disorders, affecting an estimated seven million people in the United States.

"Cala Health has emerged a pioneer in treating ET for the upper limbs through peripheral nerve stimulation. The Cala Trio delivers precise electrical pulses to the median and radial nerves in the wrist, which in turn target the central tremor network to address the underlying cause of ET. The therapy is a more convenient method of managing the condition without systemic side effects," said Neeraj Jadhav Industry Analyst. "Compared to surgical procedures, Cala Trio is cost effective, causes no patient downtime, and allows patients to control the pulses' intensity based on their comfort level."

According to the PROSPECT study presented in September 2019, physicians, patients, and objective motion sensors reported statistically significant improvement in tremor after three months of daily use. About 62 percent of the patients experienced reduced tremor severity according to physician-rated scales, while patient-rated scales indicated 68 percent of patients. Importantly, an endpoint analysis of motion sensor data demonstrated that 54 percent of patients experienced more than a 50 percent decrease in tremor power during the study period.

Cala Health supports patients, when needed, with therapy initiation and during the course of the therapy with data flowing directly from the connected devices. Due to its best-in-class engineering, it can capture the frequency of hand tremors during tasks that are assigned to patients at the onset. The accelerometers in the device measure the patients' motion, which is used by the onboard software to characterize the tremors, and provide stimulation patterns that are calibrated to the users' tremor frequency.

"In addition to ET, Cala Health's therapy is exploring applications in neurology, psychiatry, and cardiology," noted Jadhav. "Cala Health is also actively licensing technologies from academic medical centers to incorporate them in its neuromodulation platform. For instance, it licensed Partners Healthcare's and Massachusetts General Hospital's neuromodulation technology, which is based on the research on respiratory-gated vagal afferent nerve stimulation and transcutaneous vagus nerve stimulation. This commitment to innovation is expected to keep Cala ahead of the technology curve and ensure long-term success."

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.Contact us: Start the discussion.

Contact:

Harley GadomskiP: 12104778469E:harley.gadomski@frost.com

About Cala Health, Inc.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. Cala Health's lead product, Cala Trio, is the only non-invasive prescription therapy for essential tremor and is now available through a unique digital commercial model of direct-to-patient solutions. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. For more information, visit CalaHealth.com.

Photo - https://mma.prnewswire.com/media/1063788/Cala_Health_Award.jpg

SOURCE Frost & Sullivan

See original here:
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio(TM) -...

Some Neurologists Want To End Daylight Saving Time, Calling It Unhealthy – Newsweek

Posted on by

Daylight saving time (DST) officially ended in the United States at 2 a.m. on November 3, but three neurologists at Vanderbilt University say that the practice should be totally done away with permanently.

Drs. Beth A. Malow, Olivia J. Veatch and Kanika Bagai collaborated on a piece published in JAMA Neurology on Monday that brought evidence of the detrimental effects of DST on the brain, citing specifically the negative impact it may have on circadian rhythms, the internal clock that regulates the body's sleep-wake cycle.

They wrote that the transition to and from daylight saving time has been associated with several health complications, including an increased risk of stroke.

"The rate of ischemic stroke was significantly higher during the first 2 days after DST transition, with women, older age, and malignancy showing increased susceptibility," the piece read.

Studies have also indicated that the transition negatively affects sleep patterns, especially among adolescents, causing them "an average of 15 to 20 fewer minutes of sleep." The authors pointed to data indicating that teenagers averaged about 7 hours and 30 minutes of sleep per night after the transition. This, they said, was not in-line with efforts to help them get enough sleep.

"While it is important to recognize that this study only involved 40 students and was limited to the week following the DST transition," the authors wrote, "an American Academy of Sleep Medicine consensus statement has recommended 8 to 10 hours of sleep for adolescents on a regular basis."

All in all, the benefits don't outweigh the risks.

"Based on these data, we advocate for the elimination of transitions to DST," the authors wrote.

Daylight saving time has certainly not always existed, nor does it lack opponents.

Scholars of American history (and fans of the 2004 Nicholas Cage thriller, National Treasure) may recall that it was inventor and founding father Benjamin Franklin who first introduced the idea of daylight saving time in the 1780s. However, as CNN reported, the practice did not begin to be implemented widely in the United States until 1966, following the passage of the Uniform Time Act. Our current system, in which which DST runs from March to November, has only been in place since 2007.

Further, the neurologists' professional opinion may be good news for Americans, most of whom, according to a recent poll, oppose the yearly hour-switching that daylight saving time necessitates.

According to the poll, conducted by The Associated Press-NORC Center for Public Affairs Research and reported by the Associated Press, 71 percent of Americans would prefer to toss the tradition. However, respondents could not come to a consensus as to whether the country's clocks ought to stay locked on standard time or on daylight saving time all year. According to the Associated Press, 40 percent said they would prefer to keep standard time for the duration of the year, while 31 percent expressed support for always operating on daylight saving time and never switching back to standard.

Go here to see the original:
Some Neurologists Want To End Daylight Saving Time, Calling It Unhealthy - Newsweek

Vaught Neurological to expand services to Wyoming County – Beckley Register-Herald

Posted on by

Vaught Neurological Services, PLLC, is expanding to provide easier access of care to the people of Wyoming County, and BK Vaught, MD, and Rachael Riggins, MSN, FNP-C, are accepting patients at their new satellite office location in Oceana, three days a week.

OnMonday, Wednesday and Friday at 833 Cook Parkway in Oceana, they are sharingoffices with The Foot and Ankle Clinic of the Virginias, which will continue to serveits patients Tuesday and Thursday.

According to a press release, Riggins has already begun seeing patients as of Nov. 18, and Vaught will begin seeing patients Dec. 13.

The new location will offer follow-up visits for established patients who have been seen at least once in Beckley by Vaught,EMG/NCV testing for established or new patients. The testing is performed by Vaught (a board-certified EMG specialist) and is typically scheduled on Fridays, the press release stated.

All insurances are accepted, but a referral is required. All scheduling will be coordinated through the main location in Beckley.

Contact 304-252-4222 for more information, to make an appointment, or to change an existing appointment.

Email: jnelson@register-herald.com; follow on Twitter @jnelsonRH

Read the original here:
Vaught Neurological to expand services to Wyoming County - Beckley Register-Herald

Neuromuscular Disorders l Neurology l University Hospitals …

Posted on by

The neurology team at University Hospitals offers innovations in testing, diagnosis and treatment of neuromuscular diseases all in a collaborative setting to ensure our patients maintain a high quality of life.

The keys to managing a neuromuscular disorder is early detection and focused treatment. If you or your doctor suspect you have a neuromuscular issue, it is important to see a specialist as soon as possible.

For certain diseases, such as myasthenia gravis, if care is delayed, the disease can become more resistant to drug therapy, making it harder to treat. For conditions like amyotrophic lateral sclerosis (ALS), which currently has no known cure, early detection allows us to better manage ALS symptoms, extending your quality of life for as long as possible.

Our neurology team is leading research efforts with several clinical trials and pioneering nationally-funded laboratory research. Several of our experts have written comprehensive textbooks that serve as definitive resources for the treatment of neuromuscular conditions.

We also use the latest technology to diagnose and guide treatment. For example, UH has one of the few neuromuscular ultrasounds in the country allowing us to respond to neuromuscular disorders faster and more effectively. In addition, our use of electromyography (EMG) has dramatically changed the way we address disorders like entrapment neuropathy.

Our team treats a wide range of neuromuscular conditions, including:

With extensive experience and expertise in ALS treatment, University Hospitals is one of only a few facilities in the country with an ALS Clinic sponsored in part by the ALS Foundation. Through this important collaboration, we have access to groundbreaking research and technology. Our ALS dedicated team includes:

With a focus on discovering new therapies, our researchers developed a special breathing device that allows ALS patients to breathe on their own, helping them better participate in a daily routine and prolonging their quality of life. Our ALS Programbrings together specialists from the Neuromuscular Center, rehabilitative services, surgery and pulmonary medicine to deliver the best possible outcomes.

We also have a Muscular Disease Clinicthat is focused on the diagnosis and treatment of several inherited muscular disorders, including muscular dystrophy and inherited neuropathy.

In addition, our Myasthenia Gravis Programtreats patients with immunosuppressive drugs, plasma exchange and intravenous immunoglobulin.

For more information about our specialized services for neuromuscular diseases, content one of our team members at any of our convenient locationsacross the region.

Here is the original post:
Neuromuscular Disorders l Neurology l University Hospitals ...